- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hodgkin lymphoma
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Brentuximab Vedotin – July 2025
Brentuximab Vedotin; Powder for I.V. infusion 50 mg; Adcetris®
Last updated
9 July 2025